Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Bode

Showing results (561-570 of 600) with videos related to

Pageof 60
Sort By:
European Heart Journal. Acute Cardiovascular Care|October 21, 2020
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategyBatric Popovic, Emmanuel Sorbets, Jeremie Abtan, et al.
The New England Journal of Medicine|November 15, 2011
Rivaroxaban in patients with a recent acute coronary syndromeJessica L Mega, Eugene Braunwald, Stephen D Wiviott, et al.
Circulation|February 23, 2005
Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trialJean Fajadet, Marie-Claude Morice, Christoph Bode, et al.
The Lancet. Respiratory Medicine|May 17, 2021
Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trialAlexander Supady, Enya Weber, Marina Rieder, et al.
Scientific Reports|February 19, 2022
P2X<sub>4</sub> deficiency reduces atherosclerosis and plaque inflammation in miceAlexander Peikert, Sebastian König, Dymphie Suchanek, et al.
Frontiers in Cardiovascular Medicine|April 28, 2022
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic DiseaseTimoteo Marchini, Sara Malchow, Lourdes Caceres, et al.
Circulation|November 25, 2016
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment StrategyC Michael Gibson, Duane S Pinto, Gerald Chi, et al.
The New England Journal of Medicine|April 1, 2009
Early versus delayed, provisional eptifibatide in acute coronary syndromesRobert P Giugliano, Jennifer A White, Christoph Bode, et al.
Thrombosis and Haemostasis|February 22, 2021
Deficiency of Endothelial CD40 Induces a Stable Plaque Phenotype and Limits Inflammatory Cell Recruitment to Atherosclerotic Lesions in MiceMark Colin Gissler, Philipp Scherrer, Nathaly Anto-Michel, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
Pageof 60

Showing results (561-570 of 600) with videos related to

Sort By:
Pageof 60
European Heart Journal. Acute Cardiovascular Care|October 21, 2020
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategyBatric Popovic, Emmanuel Sorbets, Jeremie Abtan, et al.
The New England Journal of Medicine|November 15, 2011
Rivaroxaban in patients with a recent acute coronary syndromeJessica L Mega, Eugene Braunwald, Stephen D Wiviott, et al.
Circulation|February 23, 2005
Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trialJean Fajadet, Marie-Claude Morice, Christoph Bode, et al.
The Lancet. Respiratory Medicine|May 17, 2021
Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trialAlexander Supady, Enya Weber, Marina Rieder, et al.
Scientific Reports|February 19, 2022
P2X<sub>4</sub> deficiency reduces atherosclerosis and plaque inflammation in miceAlexander Peikert, Sebastian König, Dymphie Suchanek, et al.
Frontiers in Cardiovascular Medicine|April 28, 2022
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic DiseaseTimoteo Marchini, Sara Malchow, Lourdes Caceres, et al.
Circulation|November 25, 2016
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment StrategyC Michael Gibson, Duane S Pinto, Gerald Chi, et al.
The New England Journal of Medicine|April 1, 2009
Early versus delayed, provisional eptifibatide in acute coronary syndromesRobert P Giugliano, Jennifer A White, Christoph Bode, et al.
Thrombosis and Haemostasis|February 22, 2021
Deficiency of Endothelial CD40 Induces a Stable Plaque Phenotype and Limits Inflammatory Cell Recruitment to Atherosclerotic Lesions in MiceMark Colin Gissler, Philipp Scherrer, Nathaly Anto-Michel, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
Pageof 60